Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Academic Drug Discovery

Eric Marsault's Biography



Eric Marsault, Professor, University of Sherbrooke

After an undergraduate training at université Pierre et Marie Curie (Paris VI) and École Supérieure de Chimie Organique et Minérale (Paris), Eric Marsault obtained his Ph.D. at McGill University (Montreal, Qc, Canada) in 1996 with Pr George Just, then worked as a visiting scientist for Sanofi (Milan, Italy) prior to joining Université de Sherbrooke (Qc, Canada) as a postdoctoral fellow with Pr Pierre Deslongchamps. In 2000, he joined Néokimia (which later became Tranzyme Pharma) where he worked for 8 years as a researcher, group leader then director of medicinal chemistry. Throughout this time, the Tranzyme team matured then developed the first high throughput parallel platform to produce macrocyclic peptidomimetics, then optimized 2 clinical Ph.2 and Ph.3 candidates. In 2009, he joined Université de Sherbrooke as an Associate Professor and became Full Professor in 2015. His research focuses on the validation of emerging targets and the development of academic drug discovery, with a particular focus on peptidomimetics and macrocycles on targets such as GPCRs and transmembrane serine proteases for cardiovascular diseases, pain and infectious diseases. He is co-author of > 45 publications and co-inventor of > 35 patents. Since 2013 he is also chairman of the Institut de Pharmacologie de Sherbrooke, which focuses on the validation of emerging targets and the optimization of new drug candidates and diagnostic applications.

Eric Marsault Image

Preclinical Optimization Of Type 2 Serine Protease Inhibitors For The Treatment Of Influenza - An Academic Drug Discovery Example

Monday, 6 March 2017 at 10:15

Add to Calendar ▼2017-03-06 10:15:002017-03-06 11:15:00Europe/LondonPreclinical Optimization Of Type 2 Serine Protease Inhibitors For The Treatment Of Influenza - An Academic Drug Discovery ExampleSELECTBIOenquiries@selectbiosciences.com

Type II transmembrane Serine Proteases are emerging targets for host-based treatment of influenza. Serine trap inhibitors provide efficacious inhibition in vitro and in vivo Chemotype, mechanism of action and target confirm this is a promising host-based approach for the treatment of influenza.


Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAcademic Drug DiscoverySELECTBIOenquiries@selectbiosciences.com